Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Amicus Therapeutics, Inc.
Traded as NASDAQ: FOLD
Industry pharmaceutical
Founded February 4, 2002 (2002-02-04)
Headquarters Cranbury, New Jersey, United States
Key people
  • John Crowley (CEO)
  • Bradley Campbell (COO)
  • William Baird (CFO)
Revenue
  • Decrease US$363,000 (2013)
  • Decrease $18,411,000 (2012)
Operating income
  • Decrease ($64,181,000) (2013)
  • Decrease ($52,931,000) (2012)
Net income
  • Decrease ($59,633,000) (2013)
  • Decrease ($48,785,000) (2012)
Total assets
  • Increase $127,563,000 (2013)
  • Increase $110,088,000 (2012)
Total equity
  • Decrease $45,751,000 (2012)
  • Increase $69,220,000 (2012)
Number of employees
92 (31 Dec 2013)
Website amicusrx.com
Footnotes / references
financials

Amicus Therapeutics is a public American biopharmaceutical company based in Cranbury, New Jersey. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

The therapeutic focus of Amicus is on rare and orphan diseases, particularly disorders collectively called lysosomal storage disorders. The company's product development is based largely on the Chaperone-Advanced Replacement Therapy (CHART®) platform and has concentrated on development of enzyme replacement therapies (ERTs). In 2014, Amicus was noted as having, arguably, "the broadest portfolio of small molecule pharmacological chaperones" in the pharmaceutical industry.

As of February 2014, the company had no marketed products, its most advanced candidate being migalastat (trade name Galafold), a pharmacological chaperone treatment for Fabry disease which aims to stabilize endogenous mutant alpha-galactosidase. In parallel with advancement of migalastat monotherapy, the company engaged in a collaboration with GlaxoSmithKline and JCR Pharmaceutical to investigate coformulation with recombinant alpha-galactosidase (JR-051). This collaboration lasted for three years, from 2010 to 2013.

Amicus has no manufacturing capability of its own, relying on contract manufacturing alone.

In 2008, the company expanded from its single site in New Jersey to a second research site in San Diego.

In late 2009, the company faced a major financial setback with the termination of a multi-year collaboration agreement with Shire; at the time of the termination, financing for operations was done primarily "through private placements of our redeemable convertible preferred stock, proceeds from our initial public offering and from our prior collaboration agreement with Shire." A corporate restructuring ensued with a concomitant 20% reduction in the workforce.

In 2010, the company received a US$500,000 grant from the The Michael J. Fox Foundation to support studies conducted in collaboration with David Geffen School of Medicine at UCLA. Amicus also received in 2010 a US$210,300 grant from the Alzheimer's Drug Discovery Foundation to support pre-clinical work in collaboration with Icahn School of Medicine at Mount Sinai through the Alzheimer's Disease Research Center.

In November 2013, Amicus acquired competitor Callidus Biopharma, thereby obtaining proprietary materials and intellectual property for the enzyme replacement therapy treatment of Pompe disease.

In September 2015, the company acquired Scioderm for up to $947 million in cash and stock.

The role of chief executive officer have been vested in John F. Crowley since 2005. In 2010, Crowley succeeded Donald Hayden, Jr. as the company's chairman of the board; Hayden remained associated with Amicus through the new role of Lead Independent Director. The executive posts of chief operating officer and chief financial officer are vested in Bradley L. Campbell and William D. Baird III, respectively. As of 2010, the company's chief scientific officer was David Lockhart.

Beyond the C-Suite, as of 2010 Brandon Wustman held the post of Director of Exploratory Biology.

Investment goal date:
Dividends reinvested
Amicus Therapeutics, Inc. FOLD report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-05
--
--
Q4 2017
2018-03-01
--
--
Q4 2017
2018-02-27
--
--
Q3 2017
2017-11-08
--
--
Q3 2017
2017-11-08
2.2000
-0.6900
Q2 2017
2017-08-07
-0.3400
-0.3400
Q1 2017
2017-05-09
-0.3900
-0.3900
Q4 2016
2017-03-01
-0.4200
-0.4100
Q3 2016
2016-11-07
-0.3300
-0.3300
Q2 2016
2016-08-09
-0.4000
-0.4000
Q1 2016
2016-05-03
-0.3500
-0.3500
Q4 2015
2016-02-26
-0.3600
-0.3400
Q3 2015
2015-11-03
-0.3200
-0.3200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
7585493
BlackRock Inc.
11967596
FMR LLC
20732355
JANUS CAPITAL MANAGEMENT LLC
7136697
JENNISON ASSOCIATES LLC
9035667
MORGAN STANLEY
6128481
Palo Alto Investors, LLC
7882988
PERCEPTIVE ADVISORS LLC
17296672
Redmile Group, LLC
11375852
SECTORAL ASSET MANAGEMENT INC
4311696
STATE STREET CORP
5766929
Vanguard Group, Inc
8687760
venBio Select Advisor LLC
5097577
VICTORY CAPITAL MANAGEMENT INC
4958719
WELLINGTON MANAGEMENT CO LLP
5341132
Major Shareholders
Name Relationship
Total Shares
Holding stocks
ESSNER ROBERT
0.0100% (5814)
FOLD /
LOVE TED W
0.1900% (147814)
HAYDEN DONALD J JR
0.0100% (5814)
FOLD / INSM / VTAE /
MCGLYNN MARGARET G
0.0200% (15814)
APD / FOLD / VRTX /
PERCEPTIVE ADVISORS LLC
22.7300% (17888597)
WHEELER CRAIG A
0.0100% (5814)
AVNR / FOLD / MNTA /
BARER SOL J
0.0600% (45000)
AEGR / CFRX / FOLD / MDGN /
SBLENDORIO GLENN
0.0200% (17747)
FOLD / ICPT / MDCO / OPHT /
RAAB MICHAEL
0.0100% (5814)
ARDX / FOLD /
Campbell Bradley L
0.1600% (124472)
FOLD / PGNX /
Crowley John F
0.4200% (328001)
FOLD /
Redmile Group, LLC
16.4600% (12956446)
ARRY / FOLD /
Kirk John
0.0100% (5687)
FOLD /
Valenzano Ken
0.0400% (27687)
FOLD /
Peist Kenneth
0.0200% (18874)
FOLD /
Dilone Enrique
0.0400% (30688)
FOLD /
Quimi Daphne
0.0700% (54676)
FOLD /
Baird William D III
0.1200% (95121)
FOLD /
Gershkowitz Jayne
0.0100% (5693)
FOLD /
Castelli Jeff
0.0300% (25000)
FOLD /
Do Hung
0.6000% (473207)
FOLD /
Barth Jay
0.0800% (64184)
FOLD /
Andrews Kurt J.
0.0400% (34737)
FOLD /
David Allsop
0.0600% (50000)
FOLD /
Baldry Mark
0.0300% (25000)
FOLD /
% ()